Verona Pharma
plc
("Verona Pharma" or the
"Company")
Verona Pharma
reports positive results from RPL554 dose-finding study
Study
demonstrates drug has substantial bronchodilator effect and
excellent tolerability at broad range of doses
Data continues to
suggest drug could be meaningful new addition, alone or in
combination, for the treatment of COPD
15 March 2016, Cardiff –
Verona Pharma plc (AIM: VRP.L), the drug development company
focused on first-in-class medicines to treat respiratory diseases,
today announces positive headline data from a Phase IIa
dose-finding clinical study using the Company’s new proprietary
nebulised formulation of RPL554. RPL554 is a novel inhaled
PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory
properties in the same molecule, currently in development as a
nebulised treatment for acute exacerbations in chronic obstructive
pulmonary disorder (COPD) patients in a hospital or home-care
setting. Such patients typically require additional bronchodilation
as well as anti-inflammatory treatment despite being on maximum
doses of approved COPD medications (which often contain
salbutamol).
Highlights
-
Primary objective of study met
-
The maximum bronchodilator effect of RPL554 in this study was
comparable to the effect observed with the supramaximal dose
(7.5mg) of nebulised salbutamol used in this study2
Dr Jan-Anders Karlsson, the CEO
of Verona Pharma, said:
“We are very excited by the results
from our dose-finding study for RPL554. It is very pleasing that
the maximum bronchodilator effect of RPL554 is comparable to that
seen with the highest dose of salbutamol used in the study - a dose
equivalent to the highest dose of salbutamol used to treat acute
exacerbations of COPD in the emergency department - it is
noteworthy that this was achieved with fewer adverse events. The
data generated in this study emphasises its pronounced
bronchodilator effect, and combined with its unique
anti-inflammatory effects, we continue to believe that RPL554 could
be an important, and much needed, new treatment option, either
alone or as an add-on to existing drugs, for patients with
COPD.”
Professor Leif Bjermer of Skane
University, Lund, Sweden, lead
investigator on this study, commented:
“This well-designed and successfully executed dose-ranging
study of nebulised RPL554 in moderate asthmatics demonstrated the
drug has a linear and thus predictable pharmacokinetic profile, and
produced similar bronchodilation but with less side effects
compared to a very high dose of salbutamol, used as a comparator.
The drug was well tolerated, and few adverse events were recorded.
Together, this suggests that the drug could have a large
therapeutic index. With further clinical testing, RPL554 could
become an important, and much needed novel treatment option, for
patients with COPD and other airway’s disease.”
The intent of the study was to demonstrate a dose-dependent
bronchodilator effect of RPL554 and compare to nebulised
salbutamol. In the hospital setting, the usual starting nebulised
dose of salbutamol is 2.5mg but occasionally up to 3 times this
dose (7.5mg) is used to produce additional bronchodilation in
severely ill patients. We compared RPL554 to both the standard dose
and the very high dose of salbutamol to evaluate maximum
bronchodilator effects and tolerability.
In this randomised, double-blind, placebo-controlled, seven way
crossover Phase IIa study, 29 patients with mild to moderate
persistent asthma each received four doses of nebulised RPL554 (0.4
to 24 mg), as well as two doses of nebulised salbutamol (2.5mg and
7.5mg), or placebo. In addition to the largest dose tested in
previous studies (24mg), lower doses of the new proprietary
nebulised formulation of RPL554 than had been used before, were
explored to identify a minimally effective dose. The study was
performed at Celerion (Belfast, Ireland) and Skane University Hospital
(Lund, Sweden).
The study met its primary objective, with nebulised RPL554
demonstrating a dose-dependent bronchodilator response in asthma
patients. RPL554 pharmacokinetics were linear across the whole dose
range. At the highest doses of both compounds, RPL554 produced the
same maximum bronchodilator effect as salbutamol. Even the lowest
RPL554 dose of 0.4mg was significantly superior (p<0.0001) to
placebo as a bronchodilator. All doses of RPL554 were found to be
well tolerated and the data supports the use of RPL554 in a twice
daily dosing regimen. There were no reports of serious adverse
events and fewer adverse events were seen with RPL554 than with
salbutamol. Salbutamol produced well-acknowledged adverse events
for this drug including tremor, tachycardia, palpitations, and a
reduction in blood potassium levels. The large dosing range (60
fold) of RPL554 suggests a potentially large therapeutic index.
RPL554 is currently in development as a nebulised treatment for
acute exacerbations in COPD patients in a hospital or home-care
setting. The data from the study reported today will help inform
dose selection in the Phase IIb trial, which it is currently
expected to commence in early 2017.
The nebuliser bronchodilator market was worth about $1 billion in 2014 in the US.3 RPL554
has potential as a novel drug for the maintenance therapy of COPD,
and for patients with asthma and cystic fibrosis.
References
1 The study was carried out in asthmatics as
typically a dose response relationship to bronchodilators can be
more accurately established in this group of patients, compared to
COPD patients
2 Salbutamol is probably the most effective and
widely used bronchodilator in asthma and COPD patients. The typical
nebulised salbutamol dose range is 2.5mg and sometimes 5mg. A 7.5mg
dose of nebulised salbutamol is sometimes used to treat acute
exacerbations of COPD or asthma in the emergency department = a
supramaximal dose
3 IMS Consulting Group market research 2014
-Ends-
For further information please
contact:
Verona Pharma plc |
Tel: +44 (0)20 7863 3300 |
Jan-Anders Karlsson, CEO |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway / Julia Phillips |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a dual
phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. In addition, the Company
is exploring the potential of the drug in different diseases, such
as cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the UK Cystic Fibrosis
Trust.
About Lung and Allergy, Clinical Trial
Unit (CTU), Skane University Hospital, Lund, Sweden
The Lung and Allergy clinical trial unit at Skane
(http://www.akcsyd.se/forskning/provningsenheten) has been working
mainly with early phase II and III studies in Asthma and or COPD
for 10 years. The CTU is a part of an academic respiratory research
network group run by Professor Leif
Bjermer, a recognised expert in this field. The scientific
work is focused on disease mechanisms in asthma and COPD,
identifying and validating potential new treatment targets by means
of invasive and non-invasive techniques, advanced histology, cell
and molecular biology. The CTU is equipped with a complete
respiratory physiology lab with a special focus on techniques that
can address small airway pathology. Biomarkers, biogenetics and
functional imaging is also part of the explorative profile.
Invasive studies with bronchoscopy, biopsies, brushing and lavage
are also performed.
About Celerion Belfast- Center of Excellence for
Respiratory (www.celerion.com)
Celerion is a member of the UK’s Translational Research
Partnership in Respiratory which is a unique cooperative of
internationally leading clinicians and scientists whose aim is to
improve the speed of developing innovative therapies for
respiratory diseases by working in collaboration with research
groups of the pharmaceutical industry. They have been recognized
for their excellence in basic and translational research in
respiratory medicine.
About Chronic Obstructive Pulmonary
Disease (COPD)
Sixty-five million people worldwide suffer from moderate to
severe COPD and the World Health Organisation (WHO) expects COPD to
be the third leading cause of death globally by 2020. It is
the only major chronic disease with increasing mortality.
Currently available drugs are aimed at long-term maintenance
therapy, with the market dominated by large pharma. Despite
the wide availability of these therapies, COPD patients suffer
acute periods of worsening symptoms (exacerbations), which cause,
in the US alone, some 1.5 million A&E visits, 726,000
hospitalisations and 120,000 deaths per annum.
About Asthma
Asthma remains one of the most common chronic diseases in the
world and is characterised by recurrent breathing problems and
symptoms such as breathlessness, wheezing, chest tightness, and
coughing. In the U.S. asthma accounts for approx. 1.9 million
annual emergency room visits and approx. 500,000 annual
hospitalisations.
About Cystic Fibrosis
Cystic fibrosis (CF) is an orphan disease that afflicts
approximately 70,000 people worldwide. The disease affects mostly
the lungs, and also the pancreas, liver, and intestine. Difficulty
breathing is the most serious symptom and results from frequent
lung infections. CF is caused by one of many different mutations in
the gene for the protein cystic fibrosis transmembrane conductance
regulator (CFTR). This protein is required to regulate the
components of sweat, digestive fluids, and mucus. Healthy people
have two working copies of the CFTR gene. Carriers have one
working copy. People with CF have no working copy. CF therefore has
autosomal recessive inheritance. The underlying mechanism is
abnormal transport of chloride and sodium across the epithelium,
which is the cell layer that covers membranes over organs.
This leads to thick, viscous secretions. Individuals with CF
can be diagnosed before birth by genetic testing or by a sweat test
in early childhood. The name cystic fibrosis refers to the
characteristic scarring (fibrosis) and cyst formation within the
pancreas, first recognised in the 1930s.